HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

AbstractBACKGROUND:
Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and have been implicated in breast, ovarian, colorectal, and lung cancer growth. We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity.
PATIENTS AND METHODS:
BAY 12-9566 was orally administered daily at four dose levels; 400 mg daily, 400 mg b.i.d., 400 mg t.i.d., and 800 mg b.i.d. Drug disposition was determined on days 1 and 29 with weekly trough levels measured during the first four weeks. Plasma vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and urinary pyridinoline and deoxypyridinoline crosslinks were determined at baseline, once weekly for four weeks, and then every four weeks.
RESULTS:
Thirteen patients were entered on trial. BAY 12-9566 was well tolerated, with only one grade 3 headache, one grade 3 anemia, one grade 3 thrombocytopenia, and no musculoskeletal effects. The median treatment duration was 57 days (range 7-560). Mean trough levels of BAY 12-9566 on day 28 ranged from 80.5 to 108.6 mg/l. Plasma trough levels were 1500-42,000-fold above the Ki's for MMP-2, MMP-3, and MMP-9 at the 800 mg p.o. b.i.d. dose level. There was no significant change in VEGF, bFGF, pyridinoline, and deoxypyridinoline crosslinks with BAY 12-9566 administration.
CONCLUSIONS:
The recommended dose for further testing is 800 mg p.o. b.i.d.
AuthorsC Erlichman, A A Adjei, S R Alberts, J A Sloan, R M Goldberg, H C Pitot, J Rubin, P J Atherton, G G Klee, R Humphrey
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 12 Issue 3 Pg. 389-95 (Mar 2001) ISSN: 0923-7534 [Print] England
PMID11332153 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amino Acids
  • Antineoplastic Agents
  • Biphenyl Compounds
  • Endothelial Growth Factors
  • Enzyme Inhibitors
  • Lymphokines
  • Matrix Metalloproteinase Inhibitors
  • Organic Chemicals
  • Phenylbutyrates
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Fibroblast Growth Factor 2
  • pyridinoline
  • deoxypyridinoline
  • Bay 12-9566
  • Matrix Metalloproteinases
Topics
  • Adult
  • Amino Acids (metabolism)
  • Antineoplastic Agents (administration & dosage, pharmacokinetics, therapeutic use)
  • Biphenyl Compounds
  • Dose-Response Relationship, Drug
  • Endothelial Growth Factors (metabolism)
  • Enzyme Inhibitors (administration & dosage, pharmacokinetics, therapeutic use)
  • Female
  • Fibroblast Growth Factor 2 (metabolism)
  • Humans
  • Lymphokines (metabolism)
  • Male
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases (blood)
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoplasms (drug therapy, enzymology)
  • Organic Chemicals
  • Phenylbutyrates
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: